The estimated Net Worth of Aaron L Schacht is at least $2.83 Million dollars as of 24 September 2018. Mr. Schacht owns over 400 units of Elanco Animal Health Inc stock worth over $5,792 and over the last 6 years he sold ELAN stock worth over $0. In addition, he makes $2,826,310 as Executive Vice President - Innovation, Regulatory, and Business Development at Elanco Animal Health Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Schacht ELAN stock SEC Form 4 insiders trading
Aaron has made over 1 trades of the Elanco Animal Health Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 400 units of ELAN stock worth $9,600 on 24 September 2018.
The largest trade he's ever made was buying 400 units of Elanco Animal Health Inc stock on 24 September 2018 worth over $9,600. On average, Aaron trades about 31 units every 0 days since 2018. As of 24 September 2018 he still owns at least 400 units of Elanco Animal Health Inc stock.
You can see the complete history of Mr. Schacht stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Aaron Schacht biography
Aaron L. Schacht serves as Executive Vice President - Innovation, Regulatory, Business Development of the Company. Mr. Schacht served as the Vice President of global research and development of the Elanco Animal Health division of Lilly from 2015 to September 2018. Prior to 2015, Mr. Schacht served in various leadership roles for Lilly, including Global Brand Development Leader of Pain in Lilly BioMedicines in 2014, Senior Advisor of Strategy & Business Development for Lilly BioMedicines from 2012 to 2014, and Executive Director of Global External R&D at Lilly from 2008 to 2012.
What is the salary of Aaron Schacht?
As the Executive Vice President - Innovation, Regulatory, and Business Development of Elanco Animal Health Inc, the total compensation of Aaron Schacht at Elanco Animal Health Inc is $2,826,310. There are 4 executives at Elanco Animal Health Inc getting paid more, with Jeffrey Simmons having the highest compensation of $15,801,800.
How old is Aaron Schacht?
Aaron Schacht is 52, he's been the Executive Vice President - Innovation, Regulatory, and Business Development of Elanco Animal Health Inc since 2018. There are 15 older and 11 younger executives at Elanco Animal Health Inc. The oldest executive at Elanco Animal Health Inc is R. David Hoover, 74, who is the Independent Chairman of the Board.
What's Aaron Schacht's mailing address?
Aaron's mailing address filed with the SEC is C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD, IN, 46140.
Insiders trading at Elanco Animal Health Inc
Over the last 6 years, insiders at Elanco Animal Health Inc have traded over $1,626,280,000 worth of Elanco Animal Health Inc stock and bought 657,104 units worth $14,225,149 . The most active insiders traders include Aktiengesellschaft Bayer Wo..., Scott D.Sachem Head Capital..., and R David Hoover. On average, Elanco Animal Health Inc executives and independent directors trade stock every 38 days with the average trade being worth of $14,011,833. The most recent stock trade was executed by Michael J Harrington on 22 August 2024, trading 3,500 units of ELAN stock currently worth $51,975.
What does Elanco Animal Health Inc do?
elanco is a global animal health company. our vision: food and companionship enriching life. elanco fulfills this vision through three primary pursuits: - helping deliver a safe, more affordable, more abundant food supply by improving the health and performance of animals - helping pets live longer, healthier, higher-quality lives - improving food safety elanco employees are empowered to preserve elanco’s common culture of humility, discipline and involvement. we have a responsibility to connect and contribute to our cause, to be passionate about delivering solutions and value to our customers, and to embrace opportunities for personal and professional growth and development. through innovative products, quality systems and a shared vision, elanco strives daily to enhance animal health—and enrich the lives of people worldwide.
What does Elanco Animal Health Inc's logo look like?
Complete history of Mr. Schacht stock trades at Elanco Animal Health Inc
Elanco Animal Health Inc executives and stock owners
Elanco Animal Health Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Simmons,
President, Chief Executive Officer, Director -
Sarena Lin,
Executive Vice President, Global Marketing, Corporate Strategy and Transformation -
David Kinard,
Executive Vice President of Human Resources -
David Urbanek,
Executive Vice President - Manufacturing, Quality -
Aaron Schacht,
Executive Vice President - Innovation, Regulatory, Business Development -
Todd Young,
Chief Financial Officer, Executive Vice President -
Jeffrey N. Simmons,
Pres, CEO & Director -
Todd S. Young,
Exec. VP of Corp. Governance and Strategy & CFO -
R. David Hoover,
Independent Chairman of the Board -
Kapila Anand,
Independent Director -
Lawrence Kurzius,
Independent Director -
Michael Harrington,
Independent Director -
John Bilbrey,
Independent Director -
Denise Scots-Knight,
Independent Director -
Kirk McDonald,
Independent Director -
Deborah Kochevar,
Independent Director -
Art Garcia,
Independent Director -
Joshua Smiley,
Independent Director -
Aarti Shah,
Independent Director -
David Ricks,
Independent Director -
Carl McMillian,
Independent Director -
James Meer,
Chief Accounting Officer, Vice President -
Ramiro Cabral,
Executive Vice President - Elanco International -
Michael-Bryant Hicks,
Executive Vice President, General Counsel, Corporate Secretary -
Larbi Van Lier,
Sr. VP of Asia -
Shawn McKee,
Sr. VP of U.S. Companion Animal -
David Alan Urbanek,
Exec. VP of Manufacturing & Quality -
Ramiro Martin Cabral,
Exec. VP of Elanco International -
Racquel Harris Mason,
Exec. VP & Chief Marketing Officer -
Marcela A. Kirberger,
Exec. VP, Gen. Counsel & Corp. Sec. -
Tiffany Ann Kanaga,
Head of Investor Relations -
David S. Kinard,
Exec. VP of HR Corp. Affairs & Admin. -
Chris Keeley,
Sr. VP & Chief Information Officer -
James M. Meer,
VP & Chief Accounting Officer -
De Simas Jose Manuel Correia,
SEE REMARKS -
Lilly & Co Eli,
10% owner -
Timothy J Bettington,
SEE REMARKS -
Aktiengesellschaft Bayer Wo...,
-
Racquel Harris Mason,
See Remarks -
Dirk Ehle,
Ex VP & Pres Elanco Europe -
Joyce J. Lee,
Ex VP Prs US Pet Hlth Com Op -
Rajeev A. Modi,
SEE REMARKS -
Paul Herendeen,
-
Marcela A. Kirberger,
SEE REMARKS -
William F Doyle,
-
Scott D.Sachem Head Capital...,
-
Brabander Ellen De,
SEE REMARKS -
Shiv O'neill,
GC AND CORP SEC -
Grace Mc Ardle,
EVP, MANUFACTURING AND QUALITY